<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03540615</url>
  </required_header>
  <id_info>
    <org_study_id>19150</org_study_id>
    <secondary_id>2017-001496-23</secondary_id>
    <nct_id>NCT03540615</nct_id>
  </id_info>
  <brief_title>BAY1830839: First in Man, Single Dose Escalation, Safety &amp; Tolerability and Pharmacokinetics</brief_title>
  <official_title>Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Increasing Single Oral Doses of BAY1830839 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to investigate

        -  the safety and tolerability of increasing single oral doses of BAY 1830839 versus
           placebo under fasted conditions

        -  the pharmacokinetics after single ascending oral doses of BAY 1830839 under fasted
           conditions
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2018</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">February 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation with safety assessment following each dose step.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of BAY1830839 in plasma</measure>
    <time_frame>Day 1, 2, 3, 4, 6 ,7, 9, and 12</time_frame>
    <description>AUC: area under the plasma concentration vs time curve from zero to infinity after single dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of BAY1830839 in plasma</measure>
    <time_frame>Day 1, 2, 3, 4, 6 ,7, 9, and 12</time_frame>
    <description>maximum observed drug concentration in plasma after single dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of treatment-emergent adverse events</measure>
    <time_frame>Up to 22 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of treatment-emergent adverse events</measure>
    <time_frame>Up to 22 days after end of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>BAY1830839</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose escalations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1830839</intervention_name>
    <description>Dose escalation in healthy male subjects</description>
    <arm_group_label>BAY1830839</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) : ≥18.5 and ≤30 kg/m*2

        Exclusion Criteria:

          -  Relevant diseases within the last 4 weeks prior to the first study drug administration

          -  Febrile illness within 4 weeks before the first study drug administration

          -  Known hypersensitivity to the study drugs or components of the preparations

          -  Clinically relevant findings in the physical examination
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CRS Clinical Research Services Berlin GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

